Search Results
180 items found for "Lumpy skin disease"
- GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!
plant-like” behavior in important human cell regulator, opening up a new drug target for cancer, other diseases Neuroscience Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease
- 📰 GPCR Weekly News, January 15 to 21, 2024
/3 APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease transport by CCHCR1 via direct interaction Industry News Novartis Lutathera® significantly reduced risk of disease
- Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop ...
Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-relevant
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
including expensive cost of reagents, optimizing sensor expression levels and adapting these systems to disease-relevant the development of the BERKY and the ONE-GO biosensors, designed to facilitate their application in disease
- PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer
September 2022 "G-protein-coupled receptors (GPCRs) are involved in a wide array of physiological and disease
- Combined docking and machine learning identify key molecular determinants of ligand pharmacological
September 2022 "G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases
- C5aR2 receptor: The genomic twin of the flamboyant C5aR1
the C5aR1, which has received enormous attention for its role in both acute and chronic inflammatory diseases
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases
- A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands ...
receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease
- Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
) ligands and analogues for their pharmacologic activities and potential therapeutic utility toward diseases
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Secor et al. 2021; Wold and Zhou 2018).
- Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair
chronic clinical syndrome characterized by the reduction in cardiac function and still remains the disease
- 📰 GPCR Weekly News, February 20 to 26, 2023
Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer's Disease Reviews, GPCRs, and more Cell-trafficking impairment in disease-associated LPA6 missense mutants and
- Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19...
to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases
- Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation..
Potential Implications for Idiopathic Pulmonary Fibrosis "Idiopathic pulmonary fibrosis (IPF) is a disease
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases
- TLR4 biased small molecule modulators
Moreover, the dysregulation of TLR4 contributes to numerous diseases, which highlights the importance
- GPR3 expression in retinal ganglion cells contributes to neuron survival and accelerates axonal...
optic nerve crush in mice "Glaucoma is an optic neuropathy and is currently one of the most common diseases
- 📰 GPCR Weekly News, March 25 to March 31, 2024
using next-generation GRABNE sensors Reviews, GPCRs, and more Advances in GPCRs: Structure, Mechanisms, Disease Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development In Endocrine And Metabolic Diseases
- High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and...
patient outcomes "Triple-negative breast cancer (TNBC) is a particularly aggressive and heterogeneous disease
- Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells...
Cells: Implications for Targeted Therapy "Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive disease
- A Model for the Signal Initiation Complex Between Arrestin-3 and the Src Family Kinase Fgr
suggests that Fgr interacts with arrestin-3 at multiple sites and is consistent with the locations of disease-associated
- Canonical chemokine receptors as scavenging “decoys”
However, an imbalance in the chemokine system can also contribute to various diseases, such as inflammatory
- Targeting Intracellular Allosteric Sites in GPCRs
free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Wold and Zhou 2018).
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
While these small protein GPCRs are valuable drug targets linked to serious diseases, many remain undrugged antagonist analogs have demonstrated powerful efficacies across a range of animal models spanning different disease Since many inflammatory diseases are driven by inappropriate recruitment of monocytes into tissues, CCR2 diversified portfolio of GPCR-targeted drug candidates for the treatment of cancer and other serious diseases Journal of Infectious Diseases, 199, 1525-1527. https://doi.org/10.1086/598685 · Demonstration
- β-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy
G protein-coupled receptors (GPCRs) have been shown to play integral roles in Alzheimer's disease pathogenesis
- 📰 GPCR Weekly News
GPCR Activation and Signaling Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances
- Rescue of Cell Surface Expression and Signaling of Mutant Follicle-Stimulating Hormone Receptors
Mutations in G protein-coupled receptors (GPCRs) underlie numerous diseases.